Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
164.7 USD | +0.25% | -1.71% | +6.25% |
Apr. 18 | Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... | |
Apr. 18 | AbbVie Says Potential Treatment for Giant Cell Arteritis Met Endpoints in Phase 3 Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.25% | 291B | |
+27.97% | 676B | |
+23.58% | 554B | |
-7.02% | 349B | |
+14.85% | 318B | |
+2.96% | 210B | |
-0.41% | 204B | |
-10.02% | 194B | |
-11.81% | 144B | |
-8.80% | 142B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Says Its Crohn's Disease Therapy Performed 'Significantly' Better Than Placebo in Phase 3 Maintenance Study